Sugi Predict

Sugi Predict / Compounds / SCHEMBL1126283

SCHEMBL1126283

SCHEMBL1126283

O=C(OCc1cccnc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ HTR2A P28223 1/20 0.58
▸ RAB9A P51151 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ NAMPT P43490 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ HTT P42858 2/20 0.48
▸ CYP17A1 P05093 1/20 0.48
▸ CYP19A1 P11511 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8604756 0.91 MAPT (0.55) MAPTHTR2ARAB9ANPSR1NAMPT
SCHEMBL1972455 0.84 HTR2A (0.67) MAPTHTR2ARAB9ANPSR1ALDH1A1
SCHEMBL1714950 0.84 HTR2A (0.70) MAPTHTR2ARAB9AALDH1A1MEN1
SCHEMBL8605623 0.83 MAPT (0.52) MAPTHTR2ARAB9ANPSR1NAMPT
SCHEMBL7309905 0.83 KMT2A (0.57) MAPTNAMPTALDH1A1MEN1KMT2A
SCHEMBL5827968 0.82 HTR2A (0.80) HTR2ARAB9AALDH1A1HTTGAA
SCHEMBL10938949 0.82 MAPT (0.62) MAPTRAB9ANPSR1NAMPTALDH1A1
SCHEMBL1313230 0.81 HTR2A (0.63) MAPTHTR2ARAB9ANPSR1ALDH1A1
SCHEMBL12736161 0.81 MAPT (0.72) MAPTRAB9ANPSR1ALDH1A1MEN1
SCHEMBL4008207 0.81 MAPT (0.74) MAPTRAB9ANPSR1NAMPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113226356-B Activation of pyruvate kinase R 诺沃挪第克健康护理股份公司 2025-03-04 — — CN disclosed
EP-3852791-B1 ACTIVATING PYRUVATE KINASE R NOVO NORDISK HEALTHCARE AG (CH) 2024-07-03 — — EP disclosed
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains THE SCRIPPS RESEARCH INSTITUTE 2024-04-02 — — US disclosed
US-20230055923-A1 ACTIVATING PYRUVATE KINASE R NOVO NORDISK HEALTH CARE AG (CH) 2023-02-23 — — US disclosed
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS THE SCRIPPS RESEARCH INSTITUTE 2022-06-30 — — US disclosed
CN-114127050-A Benzopyran and imidazole derivatives useful for stabilizing amyloidogenic immunoglobulin light chains 斯克利普斯研究所 2022-03-01 — — CN disclosed
EP-3852791-A1 ACTIVATING PYRUVATE KINASE R Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
WO-2020061255-A1 ACTIVATING PYRUVATE KINASE R FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
US-20140194349-A1 HIV Protease Inhibiting Compounds ABBVIE INC. (US) 2014-07-10 — — US disclosed
US-20110275637-A1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-11-10 — — US disclosed
EP-0683772-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1995-11-29 — — EP disclosed
US-5461067-A For HIV infections ABBOTT LABORATORIES (US) 1995-10-24 — — US disclosed
EP-0683772-A4 RETROVIRAL PROTEASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1995-09-27 — — EP disclosed
EP-0659181-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-06-28 — — EP disclosed
US-5354866-A Treating HIV infections ABBOTT LABORATORIES (US) 1994-10-11 — — US disclosed
WO-1994019332-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-09-01 — — WO disclosed
WO-1994005639-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1994-03-17 — — WO disclosed
EP-0578745-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1994-01-19 — — EP disclosed
WO-1992017490-A1 PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES THE UPJOHN COMPANY (US) 1992-10-15 — — WO disclosed
EP-0486948-A2 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1992-05-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055923-A1 ACTIVATING PYRUVATE KINASE R PDK1, PDK2, PKLR MAPT 3947/4885HTR2A 4385/4885RAB9A 1689/4885
US-20110275637-A1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ADIPOR2, GPR119, ADIPOR1 MAPT 4483/4885HTR2A 127/4885RAB9A 4728/4885
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS TTR, MAP1LC3B, SAAL1 MAPT 41/4885HTR2A 4375/4885RAB9A 3384/4885
US-20140194349-A1 HIV Protease Inhibiting Compounds SERPINB1, HPN, DNPEP MAPT 2176/4885HTR2A 4489/4885RAB9A 2012/4885
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains TTR, MAP1LC3B, SAAL1 MAPT 41/4885HTR2A 4375/4885RAB9A 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.